12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anti-IL-6R: Final Phase II data

Ablynx reported final 24-week data from 34 evaluable patients with moderate to severe active RA on a stable background of methotrexate in the Phase II portion of a double-blind, placebo-controlled, European Phase I/II trial evaluating IV ALX-0061 given in doses of 1 mg/kg every 4 weeks, 3 mg/kg every 4 weeks and 6 mg/kg every 8 weeks. In 24 evaluable patients whose treatment regimen remained unmodified throughout the trial, IV ALX-0061 produced ACR20 response rates at week 24 of 75% in the 1 mg/kg dose group, 100% in the 3...

Read the full 428 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >